BML Investment Partners, L.P. 13D and 13G filings for Atea Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-12-16 09:50 am Purchase |
2024-12-13 | 13D | Atea Pharmaceuticals, Inc. AVIR |
BML Investment Partners, L.P. | 7,216,312 8.500% |
1,614,233 (+28.81%) |
Filing |
| 2024-02-07 09:25 am Unchanged |
2023-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
BML Investment Partners, L.P. | 5,602,079 6.700% |
0 (Unchanged) |
Filing |
| 2024-02-07 09:14 am Purchase |
2023-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR |
BML Investment Partners, L.P. | 5,602,079 6.700% |
1,418,434 (+33.90%) |
Filing |
| 2023-10-02 11:45 am Purchase |
2023-09-25 | 13G | Atea Pharmaceuticals, Inc. AVIR |
BML Investment Partners, L.P. | 4,183,645 5.000% |
4,183,645 (New Position) |
Filing |